Please use this identifier to cite or link to this item: https://www.arca.fiocruz.br/handle/icict/9884
Title: Administration of a nondepleting anti-CD25 monoclonal antibody reduces disease severity in mice infected with Trypanosoma cruzi
Authors: Nihei, Jorge Sadao
Cardillo, Fabíola
Santos, Washington Luis Courado dos
Carvalho, Lain Carlos Pontes de
Mengele Juniior, Jose Orivaldo
Affilliation: Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, BA, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Muniz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Muniz. Salvador,BA, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil. Faculdade de Medicina de Petrópolis - FMP/FASE. Petrópolis, RJ, Brasil.
Abstract: The role of CD25+ regulatory T cells during the course of Trypanosoma cruzi infection has been previously analyzed, and the bulk of results have shown a limited role for this T cell subpopulation. In this study, we have used an IgM, nondepleting monoclonal antibody (mAb) aiming at blocking interleukin (IL)-2 activity on CD25+ T cells. The administration of this antibody 10 days before infection increased the resistance of outbred Swiss mice to the Colombian strain of T. cruzi. Anti-CD25-treated mice had lower parasitemia and augmented numbers of effector memory T cells. In addition, these animals showed higher numbers of splenic T cells secreting IFN-γ and TNF-α, both cytokines described to be involved in the resistance to T. cruzi infection. The same treatment also increased the numbers of splenic T cells that produced homeostatic and regulatory cytokines, such as IL-2 and IL-10, and CD4+CD25+ T cells. The administration of nondepleting anti-CD25 mAb at the beginning of the chronic phase, when parasites were cleared from the blood, halted the inflammatory process in the heart, without any signs of infection reactivation. These results indicate that nondepleting anti-CD25 monoclonal antibodies may be useful to treat chronic Chagas’ disease.
Keywords: Trypanosoma cruzi
Interleukin 10
Regulatory T cells
Anti-CD25
Monoclonal antibody
Mice
keywords: Trypanosoma cruzi
Camundongos
Issue Date: 2014
Publisher: Akadémiai Kiadó
Citation: NIHEI, J.; et al. Administration of a nondepleting anti-cd25 monoclonal antibody reduces disease severity in mice infected with trypanosoma cruzi. European Journal of Microbiology and Immunology, v.4, n.2, p. 128-137,2014.
DOI: DOI:10.1556/eujmi.4.2014.2.6
ISSN: 2062509X
Copyright: open access
Appears in Collections:BA - IGM - Artigos de Periódicos
IOC - Artigos de Periódicos

Files in This Item:
File Description SizeFormat 
j_niheietal_centrogoncalomuniz_2014.pdf512.99 kBAdobe PDFView/Open


FacebookTwitterDeliciousLinkedInGoogle BookmarksBibTex Format mendeley Endnote DiggMySpace

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.